IVA Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Inventiva S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.72 |
| 52 Week High | €5.05 |
| 52 Week Low | €2.69 |
| Beta | 0.98 |
| 1 Month Change | 12.73% |
| 3 Month Change | 9.57% |
| 1 Year Change | 24.00% |
| 3 Year Change | -74.09% |
| 5 Year Change | n/a |
| Change since IPO | -72.28% |
Recent News & Updates
Shareholder Returns
| IVA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.5% | 0.7% | 1.2% |
| 1Y | 24.0% | 5.0% | 27.7% |
Return vs Industry: IVA exceeded the US Biotechs industry which returned 5% over the past year.
Return vs Market: IVA underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| IVA volatility | |
|---|---|
| IVA Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: IVA has not had significant price volatility in the past 3 months.
Volatility Over Time: IVA's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 122 | Frederic Cren | www.inventivapharma.com |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Inventiva S.A. Fundamentals Summary
| IVA fundamental statistics | |
|---|---|
| Market cap | US$185.89m |
| Earnings (TTM) | -US$119.50m |
| Revenue (TTM) | US$25.07m |
7.4x
P/S Ratio-1.6x
P/E RatioIs IVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVA income statement (TTM) | |
|---|---|
| Revenue | €23.16m |
| Cost of Revenue | €1.02m |
| Gross Profit | €22.15m |
| Other Expenses | €132.57m |
| Earnings | -€110.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 31, 2024
| Earnings per share (EPS) | -2.11 |
| Gross Margin | 95.61% |
| Net Profit Margin | -476.73% |
| Debt/Equity Ratio | -148.3% |
How did IVA perform over the long term?
See historical performance and comparison